

Original Paper

Identification of Novel MicroRNAs and Their Targets in Leukemia Cancers: A Computational Approach

Adham Fani Maleki¹, Balal Sadeghi^{2*}, Mohammad Hadi Sekhavati³, Habib MotieGhader⁴

ABSTRACT

MicroRNAs (miRNAs), one of the most abundant groups of regulatory non coding RNAs in multicellular organisms, play important roles in many fundamental cellular processes. More than four hundred miRNAs have been identified in humans and the deregulated expression of miRNA has been also shown in many cancers. Despite the postulated involvement of miRNAs in tumorigenesis, there are only a few examples where an oncogene or a tumour suppressor has been identified as a miRNA target. Here, we present an in silico analysis of potential miRNA- MYC interactions. We showed evidence for the regulation of c-MYC, one of the most potent and frequently deregulated oncogenes, via the predicted binding site in transcriptional and post transcriptional regions. In this work, bioinformatics approach for the prediction and validation of possible targets for miRNAs has been used. A list of putative targets is available and validation of which would be experimentally validated.

Key words: MicroRNAs, MYC, Leukemia Cancers, Computational Approach

Currently MicroRNAs (miRNAs) considered as outstanding class of sSmall regulatory non-coding RNAs (1). MiRNAs are single-stranded consist of 18-24 nucleotides (nt) in length transcripts cleaved from 70- to 100-nt hairpin precursors by RNase III-type enzyme and are encoded in the genomes (2).

The mature miRNA has ability to regulate gene expression by inhibiting translation and/or by inducing degradation of target messenger RNAs (3). MicroRNAs are important to cell function because of their ability to control mRNA translation (4).

Author Information:

1Embryonic and Stem Cell Biology and Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.

2Department of Food Hygiene and Public Health, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran.

3Department of Animal Science, Ferdowsi University of Mashhad, Mashhad, Iran.

4Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.

References

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *cell*. 2004;116(2):281-97.
2. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proceedings of the National Academy of Sciences of the United States of America*. 2004;101(9):2999-3004.
3. Bandyopadhyay S, Mitra R, Maulik U, Zhang MQ. Development of the human cancer microRNA network. *Silence*. 2010;1(1):6.
4. Qian J, Siragam V, Lin J, Ma J, Deng Z. The role of microRNAs in the formation of cancer stem cells: Future directions for miRNAs. *Hypothesis*. 2011;9(1).

According to various studies, miRNAs has critical role(s) in various regulatory processes such as embryonic development, protein secretion, viral infection, cell self-renewal/differentiation, cell division and cell proliferation (4). Several scientific reports stated that many miRNAs, referred to as onco/tumor suppressor miRNAs, play role (s) in the development of various human malignancies (5-8). Aberrant expression of miRNAs involved to carcinogenesis by promoting the expression of proto-oncogenes or by inhibiting the expression of tumor suppressor genes (3). In addition, it is about 50% of genes that encoding miRNAs are located in cancer associated genomic regions (CAGR) or fragile sites (2). Various types of leukemia including: acute_lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML) and Chronic lymphocytic leukemia__(CLL) has been researched extensively from miRNAs point of view and currently it has been identified several miRNAs involved in all types of leukemia (3). miR-15a-16-1_was the first miRNAs identified as regulator of CLL (9). Currently there are several miRNAs identified and verified in different type of leukemia cancers (10). miRNAs_MiRNAs not only arouse interest among researchers studying molecular mechanism and also gene regulation in different type of malignancies but also they theoretically represent therapeutic targets.




Figure 1: A) MicroRNAs as oncogenes or tumour suppressor genes B) Strategies to target the MYC miRNA interplay in cancer.

References

- Melo SA, Esteller M, editors. Disruption of microRNA nuclear transport in human cancer. Seminars in cancer biology; 2014: Elsevier.
- Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. MicroRNA Cancer Regulation: Springer; 2013. p. 1-20.
- Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis. 2012;33(6):1126-33.
- Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. The Journal of pathology. 2011;223(2):102-15.
- Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524-9. PMID: 12434020. DOI: 10.1073/pnas.242606799.
- Xie B, Ding Q, Han H, Wu D. miRCancer: a microRNA-cancer association database constructed by text mining on literature. Bioinformatics. 2013;29(5):638-44. PMID: 23325619. DOI: 10.1093/bioinformatics/btt014.




Figure 2: Interactions between MYC-associated miRNAs and their potential mRNA targets

Hence, search for new miRNAs with computational approaches could be useful for better understanding of molecular pathways as well as possible new drugs (11).

MYC plays a role as transcription factor that involved in cell cycle and cell growth by acting downstream of many ligand membrane receptor complexes and signal transduction pathways. (12). MYC is also a proto-oncogene that contributes to the genesis of many human cancers (Figure 1) (11).

Currently there are strong evidences that MYC has critical roles in molecular pathways involved in Hodgkin lymphomas and also chronic lymphocytic leukemia (CLL) (12). Over expression of MYC in B lymphocytes is to be sufficient to increase cell growth that could be unlinked from cell proliferation. In addition, its central role in the growth programs of T lymphocytes. These evidences demonstrate necessity of study on common miRNAs in different leukemia types as possible regulator of MYC. In this study, at the first phase we evaluated MYC genome; 3' UTR, 5' UTR and also promoter to find possible new miRNAs (s). In the second phase, potential of common miRNAs in different leukemia types for possible interaction with MYC has been evaluated.

Material and Methods

A: Computational approach to miRNAs gene finding

The UTR sequences were retrieved from GenBank. The current GeneBank format was converted to a FASTA file. In order to identify potential and possible hairpin structures of miRNAs genes in MYC within the area of interest (5' UTR, 3' UTR, intronic and promoter), SCC profiler (13) and miPRED (14) online classifier (<http://www.bioinf.seu.edu.cn/miRNA>) programs were employed.

For the identification of putative miRNAs precursors in MYC introns CID-miRNA was used along with the prediction of Dorsha processing sites using Microprocessor SVM program (15, 16).

References:

11. Mraz M, Pospisilova S. MicroRNAs in chronic lymphocytic leukemia: from causality to associations and back. *Expert Rev Hematol.* 2012;5(6):579-81.
12. Rossi D. MYC addiction in chronic lymphocytic leukemia. *Leukemia & lymphoma.* 2013;54(5):905-6.
13. Oulas A, Boutla A, Gkirtzou K, Reczko M, Kalantidis K, Poirazi P. Prediction of novel microRNA genes in cancer-associated genomic regions—a combined computational and experimental approach. *Nucleic acids research.* 2009:gkp120.
14. Jiang P, Wu H, Wang W, Ma W, Sun X, Lu Z. MiPred: classification of real and pseudo microRNA precursors using random forest prediction model with combined features. *Nucleic acids research.* 2007;35(suppl 2):W339-W44.
15. Tyagi S, Vaz C, Gupta V, Bhatia R, Maheshwari S, Srinivasan A, Bhattacharya A. CID-miRNA: a web server for prediction of novel miRNA precursors in human genome. *Biochemical and biophysical research communications.* 2008;372(4):831-4.
16. Helvik SA, Snøve O, Sætrom P. Reliable prediction of Drosha processing sites improves microRNA gene prediction. *Bioinformatics.* 2007;23(2):142-9.

Running Title: Identification of Novel MicroRNAs

miRBase (<http://www.mirbase.org/index.shtml>) database was also used to determine the degree of conservation of miRNAs and its precursor sequence along with blat search against human genome (17). The folding temperature was set to 37°C. We used a cut-off value -18 kcal/mol.

B: Computational approach to target prediction

DIANA-microT web server was employed in order to find potential target MYC for miRNAs (18, 19).

The prediction was also performed by using RNAhybrid (20, 21), targetscan (http://www.targetscan.org/vert_61/), mirtarbase (<http://mirtarbase.mbc.nctu.edu.tw/>), EIMMo (<http://www.mirz.unibas.ch/EIMMo3/index.php>), mirdb (<http://mirdb.org/miRDB/>), MatureBayes(18), pmirp (22) and mirz (23) online tools. Diana-mirpath (24) and geneset2miRNA (25) online tools used to find the pathways in which MYC-miRNAs is involved. Also, for extraction of common miRNAs in different types of leukemia cancers miRCancer and dbDEMC were developed (25, 26). The basis of the assumption that the epistatically interacting genes operated in the same pathway, to search for the co-expression of miRNA target genes with miRNA host gene, GENEMANIA online tool was used (27).

References

17. Kent WJ. BLAT—the BLAST-like alignment tool. *Genome research*. 2002;12(4):656-64.
18. Maragkakis M, Alexiou P, Papadopoulos GL, Reczko M, Dalamagas T, Giannopoulos G, Goumas G, Koukis E, Kourtis K, Simossis VA. Accurate microRNA target prediction correlates with protein repression levels. *BMC bioinformatics*. 2009;10(1):295.
19. Maragkakis M, Reczko M, Simossis VA, Alexiou P, Papadopoulos GL, Dalamagas T, Giannopoulos G, Goumas G, Koukis E, Kourtis K. DIANA-microT web server: elucidating microRNA functions through target prediction. *Nucleic acids research*. 2009:gkp292.
20. Rehmsmeier M, Steffen P, Höchsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. *Rna*. 2004;10(10):1507-17.
21. Krüger J, Rehmsmeier M. RNAhybrid: microRNA target prediction easy, fast and flexible. *Nucleic acids research*. 2006;34(suppl 2):W451-W4.
22. Zhao D, Wang Y, Luo D, Shi X, Wang L, Xu D, Yu J, Liang Y. PMirP: A pre-microRNA prediction method based on structure–sequence hybrid features. *Artificial intelligence in medicine*. 2010;49(2):127-32.
23. Sewer A, Paul N, Landgraf P, Aravin A, Pfeffer S, Brownstein MJ, Tuschl T, van Nimwegen E, Zavolan M. Identification of clustered microRNAs using an ab initio prediction method. *BMC bioinformatics*. 2005;6(1):267.
24. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M, Hatzigeorgiou AG. DIANA-mirPath: Integrating human and mouse microRNAs in pathways. *Bioinformatics*. 2009;25(15):1991-3.
25. Antonov AV, Dietmann S, Wong P, Lutter D, Mewes HW. GeneSet2miRNA: finding the signature of cooperative miRNA activities in the gene lists. *Nucleic acids research*. 2009;37(suppl 2):W323-W8.
26. Xie B, Ding Q, Han H, Wu D. miRCancer: a microRNA–cancer association database constructed by text mining on literature. *Bioinformatics*. 2013:btt014.
27. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic acids research*. 2010;38(suppl 2):W214-W20.

Results and Discussion

The goal of the bioinformatics analysis was to find potential binding sites in the set of human MYC oncogene. In humans, as in other animals, the miRNA regulation is accomplished by binding the miRNAs predominantly to the 3' untranslated region (UTR) of the messenger RNA (28-30). For this reason the investigation and scanning for miRNA:mRNA binding sites was limited to this sequences of Homo sapiens. In first, we could not find any region of Myc gene with potentials change to miRNA genes. After the scanning and filtering of the MYC dataset and miRNA genes, positive results for binding sites in sequences.

(MYC genes) from this set were obtained. Supplementary material presents an arbitrary selection of known MYC-genes with their predicted miR-regulators of the analysis. The result was then graphed using GENEMANIA to show the interactions between MYC-associated miRNAs and their potential mRNA targets. The nodal nature of the targets and their overlaps suggests that MYC-associated miRNAs work in concert. We have checked checked all the human MYC potential interactions and found that they are all located in the 2/3-th region of the 3'UTR. However, there is no obligatory region that has been proven so far for the localization of the miRNA binding sites within the 3' UTR. miRNAs miRNA sites also have preferences to the of 3'UTRs sequence composition. Our *in silico* analysis revealed also an additional interaction of potential interest (Supplementary material).

Deregulation of MYC contributes to the development a wide variety of human tumors, including leukemia and neuroblastoma. Counteracting the tumor-promoting activity of MYC is therefore an appealing anticancer strategy. Approaches targeting different levels of the MYC pathway are currently being explored. With the characterization of the interplay between MYC and miRNAs, yet another layer of targeting opportunities has emerged. Thus the rapidly growing understanding of the biology of miRNAs in cancer as well as the development in RNA-mediated therapeutic approaches in recent years promises new, exciting modes of specific targeting in cancer.

More than 28000 human miRNAs have been identified so far and bioinformatics analyses predict that the total number may be increased. More than 2000 miRNAs have been already correlated with cancer. Moreover, the expression profile of miRNAs from cancer tissues has been suggested to be prognostic concerning the speed of cancer development and its malignancy. A correlation between the expression of particular miRNAs and their effects on target oncogenes followed by tumorigenesis is beginning to gain evidence. Of particular interest is the possibility that the growth of cancer cells can be repressed by artificial modulation of the level of miRNAs. Despite the accelerated research interest in the miRNA-regulation, there are only a few examples where an oncogene or a tumour suppressor has been identified as a miRNA target and the regulatory

References:

28. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. *Genes & development*. 2004;18(5):504-11.
29. box consensus AS uGGAAGAC G. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. *Nature genetics*. 2002;30:363.
30. Vella MC, Choi E-Y, Lin S-Y, Reinert K, Slack FJ. The *C. elegans* microRNA let-7 binds to imperfect let-7 complementary sites from the lin-41 3' UTR. *Genes & development*. 2004;18(2):132-7.

Running Title: Identification of Novel MicroRNAs

connection validated. Our results indicate that the correlation of the MYC gene, which is one of the critical oncogenes, is modulated by numbers of miRNAs, expanding the numbers of validated oncomirs.

Since the significant increase of miRNA targets, all previous validations (including some "oncomirs") have been gathered by Sethupathy et al, in a database called TarBase (31).

Although now there are many programmes/programs established for the computational prediction of miRNA targets(32), the large number of predicted targets makes it difficult to choose the best candidates for further experimental verification in a biological system. The advantage of our bioinformatics approach is the possibility of relatively fast, manual scanning of the secondary structures formed by analysed pairs of putative interactors through the use of the RNAfold format. It is worth noticing, that in the results list of our scanning important oncogenes can be found, that have already been proven as targets for particular miRNA (see Additional file). Based on our analysis it is not possible to specify which member(s) of the miRNAs family is (are) responsible for the down-regulation of *MYC*.

MYC is one important oncogene with the ability to induce both cell proliferation and apoptosis_(33). Moreover, *MYC* regulates the transcription of miRNAs from miR-17 cluster and two of them (miR-17-5p and miR-20) regulate transcription factor E2F1 at the translational level_(34), which is also transcriptionally activated by *MYC*_(35). A large number of potential miRNA target sites in human oncogenes has been proposed and presented here based on an *in silico* analysis. Targets for different oncomirs, experimental validation of which would be of special interest, are needed. We must design the "gold-standard" method to experimentally validate miRNA::target interactions. The miRNAs that are encoded by miRNAs family are conserved between mammalian species, both at the sequence level and at their temporal expression patterns, which probably indicates their general role in gene regulation_(36). The *MYC*, on the other hand, is one of the most potent and frequently deregulated oncoproteins in human cancers_(37, 38); therefore its deregulation is regarded as a hallmark of many cancers_(39).

References

31. 31. Sethupathy P, Corda B, Hatzigeorgiou AG. TarBase: A comprehensive database of experimentally supported animal microRNA targets. *Rna*. 2006;12(2):192-7.
32. 32. Bentwich I. Prediction and validation of microRNAs and their targets. *FEBS letters*. 2005;579(26):5904-10.
33. 33. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. *cell*. 2002;109(3):321-34.
34. 34. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. *nature*. 2005;435(7043):839-43.
35. 35. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B. Genomic targets of the human c-Myc protein. *Genes & development*. 2003;17(9):1115-29.
36. 36. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. *nature*. 2000;408(6808):86-9.
37. 37. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. *Molecular and cellular biology*. 1999;19(1):1-11.
38. 38. Prochownik EV. c-Myc as a therapeutic target in cancer. *Expert review of anticancer therapy*. 2004;4(2):289-302.
39. 39. Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ. Cancer therapeutics: targeting the dark side of Myc. *European journal of cancer*. 2005;41(16):2485-501.